计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
为什么选择此级别
，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 6 篇同行评审文献引用。
概述
PF-2341066 shows inhibition of Met phosphorylation in mIMCD3 mouse of MDCK canine epithelial cells with an IC50 of 5 nM and 20 nM, respectively, as well as NCI-H69 and HOP92 cells, with an IC50 of 13 nM and 16 nM, respectively. PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion varient of the ALK RTK expressed by the KARPAS299 human anaplastic large-cell lymphoma (ALCL) cell line. PF-2341066 supresses human GTL-16 gastric carcinoma cell growth with an IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with an IC5050 of 30 nM.
A Met inhibitor effective against various cell lines
Crizotinib has been used:
· to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis
· to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells
· to restore sensitivity to erlotinib
Information
Crizotinib (PF-02341066) Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM. Crizotinib induces autophagy t
In vitro
PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity).
In vivo
In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066. P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function. PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066. Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.
Cell Data
cell lines：
Concentrations：0-256 nM
Incubation Time：1 hour
Powder Purity:≥99%
规格
别名
克唑替尼（PF-02341066）
英文别名
1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methyl-pyrimidine-2,4-dione | NCGC00250400-09 | BB 0261738 | CRIZOTINIB [MART.] | VGH | CHEBI:64310 | DTXSID40193304 | PF 2341066 | KBio2_002584 | 3-((1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY)-5-(1-
规格或纯度
10mM in DMSO
英文名称
Crizotinib (PF-02341066)
生化机理
克唑替尼（PF-02341066）是一种强效的 c-Met 和 ALK 抑制剂，在基于细胞的检测中 IC50 分别为 11 nM 和 24 nM。它还是一种强效的 ROS1 抑制剂，Ki 值小于 0.025 nM。克唑替尼通过抑制多种肺癌细胞系中的 STAT3 通路诱导自噬。
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
名称和识别符
PubChem SID
EC号
638-814-9
分子类型
小分子
IUPAC Name
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
INCHI
1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
InChi Key
KTEIFNKAUNYNJU-GFCCVEGCSA-N
Smiles
CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Isomeric SMILES
C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
UN Number
Packing Group
III
分子量
450.34
Reaxy-Rn
12134721
Reaxys-RN link address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12134721&ln=
技术文档
高级数据
系统学分类
分类树（Taxonomy Tree）
| 界（kingdom) | 有机化合物 |
|---|---|
| 超类（Superclass) | 有机杂环化合物 |
| 类（Class) | 吡啶及其衍生物 |
| 亚类（Subclass） | 吡唑基吡啶 |
| 中间层级节点（Intermediate Tree Nodes） | 暂无 |
| 直接上位类(Direct Parent) | 吡唑基吡啶 |
| 其他上位类（Alternative Parents） | 二氯苯 烷基芳基醚 氨基吡啶及其衍生物 氟苯类 哌啶类 芳基氯化物 芳基氟化物 咪唑内酰胺类 吡唑类 杂芳族化合物 氮杂环化合物 二烷基胺 伯胺 有机氯化物 有机氟化物 有机光子化合物 碳氢化合物衍生物 |
| 分子骨架（Molecular Framework) | 芳香族杂单环化合物 |
| 取代基（Substituents） | 1,3-二氯苯 - 3-吡唑基吡啶 - 芳基醚 - 氨基酸 - 氨基吡啶 - 芳香族杂单环化合物 - 芳基氯化物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 吡唑 - 苯基化合物 - 氯苯 - 乙醚 - 氟萘 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 单环苯基基团 - 有机硝基化合物 - 有机氧化合物 - 有机氯化物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 哌嗪 - 初级胺 - 吡唑 - 二级脂肪胺 - 醛基 |
| 描述（Description） | 该化合物属于吡唑啉吡啶类有机化合物。这类化合物具有吡唑啉吡啶骨架，即通过键连接（而非缩合）的吡唑与吡啶结构单元。 |
| 外部描述符（External Descriptors） | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine |
三维结构
交互式化学结构模型
产品属性
| ALogP | 3.7 |
|---|
关联靶点（人）
EPHB6
Tchem
肝素 B 型受体 6(Ephrin type-B receptor 6)
(1 活性数据)
MST1R
Tchem
巨噬细胞刺激蛋白受体(Macrophage-stimulating protein receptor)
(1 活性数据)
ROS1
Tclin
原癌基因酪氨酸蛋白激酶ROS(Proto-oncogene tyrosine-protein kinase ROS)
(11 活性数据)
MET
Tclin
肝细胞生长因子受体(Hepatocyte growth factor receptor)
(38 活性数据)
MERTK
Tchem
酪氨酸蛋白激酶(Tyrosine-protein kinase Mer)
(1 活性数据)
TEK
Tclin
血管生成素-1受体(Angiopoietin-1 receptor)
(1 活性数据)
SLK
Tchem
STE20 类丝氨酸/苏氨酸蛋白激酶(STE20-like serine/threonine-protein kinase)
(1 活性数据)
LTK
Tclin
白细胞酪氨酸激酶受体(Leukocyte tyrosine kinase receptor)
(1 活性数据)
ABL1
Tclin
酪氨酸蛋白激酶ABL1(Tyrosine-protein kinase ABL1)
(3 活性数据)
ALK
Tclin
ALK 酪氨酸激酶受体(ALK tyrosine kinase receptor)
(33 活性数据)
AXL
Tchem
酪氨酸蛋白激酶受体UFO(Tyrosine-protein kinase receptor UFO)
(1 活性数据)
NTRK2
Tclin
BDNF/NT-3 生长因子受体(BDNF/NT-3 growth factors receptor)
(1 活性数据)
JAK2
Tclin
酪氨酸蛋白激酶JAK2(Tyrosine-protein kinase JAK2)
(2 活性数据)
ABL1
Tclin
Tyrosine-protein kinase ABL
(18331 活性数据)
EGFR
Tclin
Epidermal growth factor receptor erbB1
(33727 活性数据)
ESR1
Tclin
Estrogen receptor alpha
(17718 活性数据)
NR3C1
Tclin
Glucocorticoid receptor
(14987 活性数据)
INSR
Tclin
Insulin receptor
(5558 活性数据)
PGR
Tclin
Progesterone receptor
(8562 活性数据)
ADRB2
Tclin
Beta-2 adrenergic receptor
(11824 活性数据)
CHRM2
Tclin
Muscarinic acetylcholine receptor M2
(10671 活性数据)
ADRB1
Tclin
Beta-1 adrenergic receptor
(6630 活性数据)
HTR1A
Tclin
Serotonin 1a (5-HT1a) receptor
(14969 活性数据)
ADRA2A
Tclin
Alpha-2a adrenergic receptor
(9450 活性数据)
AR
Tclin
Androgen Receptor
(11781 活性数据)
CHRM1
Tclin
Muscarinic acetylcholine receptor M1
(12690 活性数据)
TOP2A
Tclin
DNA topoisomerase II alpha
(6317 活性数据)
IMPDH2
Tclin
Inosine-5'-monophosphate dehydrogenase 2
(1326 活性数据)
DRD2
Tclin
Dopamine D2 receptor
(23596 活性数据)
GABRA1
Tclin
GABA receptor alpha-1 subunit
(399 活性数据)
MAOA
Tclin
Monoamine oxidase A
(11911 活性数据)
CNR1
Tclin
Cannabinoid CB1 receptor
(20913 活性数据)
DRD1
Tclin
Dopamine D1 receptor
(9720 活性数据)
PTGS1
Tclin
Cyclooxygenase-1
(9233 活性数据)
SLC6A2
Tclin
Norepinephrine transporter
(10102 活性数据)
HRH2
Tclin
Histamine H2 receptor
(5428 活性数据)
HTR2A
Tclin
Serotonin 2a (5-HT2a) receptor
(14758 活性数据)
HTR2C
Tclin
Serotonin 2c (5-HT2c) receptor
(11471 活性数据)
AVPR2
Tclin
Vasopressin V2 receptor
(2912 活性数据)
ADORA1
Tclin
Adenosine A1 receptor
(17603 活性数据)
AGTR1
Tclin
Type-1 angiotensin II receptor
(5176 活性数据)
SLC6A4
Tclin
Serotonin transporter
(12625 活性数据)
CRHR1
Tclin
Corticotropin releasing factor receptor 1
(2996 活性数据)
ADRA1A
Tclin
Alpha-1a adrenergic receptor
(8359 活性数据)
PTGS2
Tclin
Cyclooxygenase-2
(13999 活性数据)
HRH1
Tclin
Histamine H1 receptor
(7573 活性数据)
OPRM1
Tclin
Mu opioid receptor
(19785 活性数据)
DRD3
Tclin
Dopamine D3 receptor
(14368 活性数据)
PPARG
Tclin
Peroxisome proliferator-activated receptor gamma
(15191 活性数据)
AVPR1A
Tclin
Vasopressin V1a receptor
(5412 活性数据)
OPRD1
Tclin
Delta opioid receptor
(15096 活性数据)
HTR3A
Tclin
Serotonin 3a (5-HT3a) receptor
(3366 活性数据)
GCGR
Tclin
Glucagon receptor
(2563 活性数据)
SLC6A3
Tclin
Dopamine transporter
(10535 活性数据)
KCNH2
Tclin
HERG
(29587 活性数据)
CACNA1C
Tclin
Voltage-gated L-type calcium channel alpha-1C subunit
(766 活性数据)
PDE3A
Tclin
Phosphodiesterase 3A
(3309 活性数据)
SLC29A1
Tclin
Equilibrative nucleoside transporter 1
(1711 活性数据)
ERBB2
Tclin
Receptor protein-tyrosine kinase erbB-2
(7851 活性数据)
PDGFRB
Tclin
Platelet-derived growth factor receptor beta
(5195 活性数据)
ADRA2B
Tclin
Alpha-2b adrenergic receptor
(4412 活性数据)
ADRA2C
Tclin
Alpha-2c adrenergic receptor
(4876 活性数据)
CHRM3
Tclin
Muscarinic acetylcholine receptor M3
(7750 活性数据)
关联靶点（其它种属）
Cdk4
Cyclin-dependent kinase 4 (3 活性数据)
Mc4r
Melanocortin receptor 4 (1205 活性数据)
Ttr
Transthyretin (14 活性数据)
Npy1r
Neuropeptide Y receptor type 1 (8 活性数据)
Cckar
Cholecystokinin A receptor (90 活性数据)
PIK3CA
PI3-kinase p110-alpha subunit (51 活性数据)
Pde4d
Phosphodiesterase 4D (4 活性数据)
Pygl
Liver glycogen phosphorylase (81 活性数据)
Prkcd
Protein kinase C delta (192 活性数据)
Prkcb
Protein kinase C beta (2 活性数据)
Abcb1b
P-glycoprotein 1 (174 活性数据)
Mapk1
MAP kinase ERK2 (650 活性数据)
Hdac1
Histone deacetylase 1 (93 活性数据)
Hdac6
Histone deacetylase 6 (222 活性数据)
Fgfr4
Fibroblast growth factor receptor 4 (138 活性数据)
Fgfr3
Fibroblast growth factor receptor 3 (21 活性数据)
Camk2g
CaM kinase II gamma (1 活性数据)
Gck
Hexokinase type IV (278 活性数据)
Tec
Tyrosine-protein kinase TEC (25 活性数据)
Staphylococcus aureus (210822 活性数据)
Escherichia coli (133304 活性数据)
Toxoplasma gondii (4585 活性数据)
Mus musculus (284745 活性数据)
Enterovirus A71 (1246 活性数据)
BaF3 (4657 活性数据)
CHO (4503 活性数据)
MDCK (10148 活性数据)
Vero (26788 活性数据)
H4 (48 活性数据)
NIH3T3 (5395 活性数据)
HT-22 (3261 活性数据)
AIRC
Multifunctional protein ADE2 (8 活性数据)
rep
Replicase polyprotein 1ab (378 活性数据)
Plasma (328 活性数据)
Slc22a3
Solute carrier family 22 member 3 (35 活性数据)
pknB
Serine/threonine-protein kinase pknB (356 活性数据)
CDPK1
Calcium-dependent protein kinase 1 (793 活性数据)
CRK2
Cell division control protein 2 homolog (194 活性数据)
Septin9
Septin-9 (1 活性数据)
Acadvl
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (1 活性数据)
Inppl1
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 (2 活性数据)
Liver microsome (341 活性数据)
SARS-CoV-2 (38078 活性数据)
作用机制
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
化学和物理性质
分子量
450.300 g/mol
XLogP3
3.700
氢键供体数Hydrogen Bond Donor Count
2
氢键受体数Hydrogen Bond Acceptor Count
6
可旋转键计数Rotatable Bond Count
5
精确质量Exact Mass
449.119 Da
单同位素质量Monoisotopic Mass
449.119 Da
拓扑极表面积Topological Polar Surface Area
78.000 Ų
重原子数Heavy Atom Count
30
形式电荷Formal Charge
0
复杂度Complexity
557.000
同位素原子数Isotope Atom Count
0
定义的原子立体中心计数Defined Atom Stereocenter Count
1
未定义的原子立体中心计数Undefined Atom Stereocenter Count
0
定义的键立体中心计数Defined Bond Stereocenter Count
0
未定义的键立体中心计数Undefined Bond Stereocenter Count
0
所有立体化学键的总数The total count of all stereochemical bonds
0
共价键合单元计数Covalently-Bonded Unit Count
1
安全和危险性（GHS）
信号词
警告
危险声明
H317: 可能引起皮肤过敏反应
H318: 造成严重的眼睛损伤
H319: 引起严重眼睛刺激
H341: 怀疑引起遗传缺陷
H400: 对水生生物有剧毒
预防措施声明
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾
P272: 被污染的工作服不允许离开工作场所
P273: 避免释放到环境中。
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P281: 根据需要使用个人防护设备。
P321: 特殊处理（请参阅此标签上的...）。
P391: 收集溢出物
P302+P352: 如皮肤沾染：用水充分清洗。
P305+P351+P338: 如进入眼睛：用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出，取出隐形眼镜。继续冲洗。
P333+P313: 如发生皮肤刺激或皮疹：求医/就诊。
P362+P364: 脱掉沾污的衣服，清洗后方可重新使用。
P405: 密闭存放
P501: 将内容物/容器处理到。。。
P203: 使用前，获取、阅读并遵守所有安全说明。
P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。
P305+P354+P338: 如果进入眼睛：立即用水冲洗几分钟。取下隐形眼镜（如果有的话），并且操作简单。继续冲洗。
P318: 如果暴露或担心，请就医。
P317: 寻求紧急医疗救助。
P337+P317: 如果眼睛刺激持续：寻求医疗帮助。
Class
9
RIDADR
UN 3077 9 / PGIII
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
 L2214589 |
分析证书 | C408520 |
技术文档和文章
此产品的引用文献
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）